| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.36 |
| 52 Week High | CN¥9.72 |
| 52 Week Low | CN¥3.67 |
| Beta | -0.33 |
| 11 Month Change | -18.50% |
| 3 Month Change | -31.12% |
| 1 Year Change | -25.09% |
| 33 Year Change | 2.59% |
| 5 Year Change | -8.60% |
| Change since IPO | -44.49% |
Recent News & Updates
Shareholder Returns
| 2693 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.8% | -5.0% | -3.6% |
| 1Y | -25.1% | -13.7% | -16.0% |
Return vs Industry: 002693 underperformed the CN Pharmaceuticals industry which returned -13.7% over the past year.
Return vs Market: 002693 underperformed the CN Market which returned -16% over the past year.
Price Volatility
| 2693 volatility | |
|---|---|
| 2693 Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002693's share price has been volatile over the past 3 months.
Volatility Over Time: 002693's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 474 | Jianming Li | www.shuangchengmed.com |
Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Fundamentals Summary
| 2693 fundamental statistics | |
|---|---|
| Market cap | CN¥1.78b |
| Earnings (TTM) | -CN¥63.99m |
| Revenue (TTM) | CN¥197.21m |
9.2x
P/S Ratio-28.4x
P/E RatioIs 2693 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2693 income statement (TTM) | |
|---|---|
| Revenue | CN¥197.21m |
| Cost of Revenue | CN¥75.70m |
| Gross Profit | CN¥121.51m |
| Other Expenses | CN¥185.50m |
| Earnings | -CN¥63.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 61.61% |
| Net Profit Margin | -32.45% |
| Debt/Equity Ratio | 32.9% |
How did 2693 perform over the long term?
See historical performance and comparison